MAGE-A Antibody (A-1): sc-515687
- MAGE-A Antibody (A-1) is a mouse monoclonal IgG1 κ provided at 200 µg/ml
- raised against amino acids 243-287 mapping near the C-terminus of MAGE-A12 of human origin
- MAGE-A Antibody (A-1) is recommended for detection of MAGE-A1, MAGE-A2, MAGE-A2B, MAGE-A3, MAGE-A4, MAGE-A6, MAGE-A8, MAGE-A9 and MAGE-A12 of human origin by WB, IP, IF and ELISA
- Anti-MAGE-A Antibody (A-1) is available conjugated to agarose for IP; HRP for WB, IHC(P) and ELISA; and to either phycoerythrin or FITC for IF, IHC(P) and FCM
- also available conjugated to Alexa Fluor® 488, Alexa Fluor® 546, Alexa Fluor® 594 or Alexa Fluor® 647 for WB (RGB), IF, IHC(P) and FCM, and for use with RGB fluorescent imaging systems, such as iBright™ FL1000, FluorChem™, Typhoon, Azure and other comparable systems
- also available conjugated to Alexa Fluor® 680 or Alexa Fluor® 790 for WB (NIR), IF and FCM; for use with Near-Infrared (NIR) detection systems, such as LI-COR®Odyssey®, iBright™ FL1000, FluorChem™, Typhoon, Azure and other comparable systems
- m-IgG Fc BP-HRP and m-IgGκ BP-HRP are the preferred secondary detection reagents for MAGE-A Antibody (A-1) for WB applications. These reagents are now offered in bundles with MAGE-A Antibody (A-1) (see ordering information below).
MAGE-A Antibody (A-1) is a mouse monoclonal IgG1 kappa light chain antibody that detects MAGE-A of human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). MAGE-A Antibody (A-1) is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. The melanoma-associated antigen (MAGE) family is crucial in cancer immunotherapy due to expression in tumors while being largely absent in normal tissues, with the notable exceptions of the testis and placenta. MAGE proteins play a significant role in immune response against tumors, as cytotoxic T lymphocytes recognize and target cancer cells. MAGE genes, initially isolated from various tumors, encode tumor-rejection antigens expressed in a wide range of tumor types, making MAGE proteins valuable targets for therapeutic strategies. Understanding MAGE protein structure is essential, as unique conformations may influence T cell receptor interactions, thereby affecting immunotherapeutic approach efficacy. Despite extensive research on MAGE genes in tumor context, precise functions in normal cells remain largely elusive, highlighting the need for further investigation into biological roles and potential therapeutic applications.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
MAGE-A Antibody (A-1) References:
- MAGE-A antigens as targets in tumour therapy. | Meek, DW. and Marcar, L. 2012. Cancer Lett. 324: 126-32. PMID: 22634429
- MAGE-A expression, immune microenvironment, and prognosis in upper urinary tract carcinoma. | Makise, N., et al. 2016. Hum Pathol. 50: 62-9. PMID: 26997439
- A Threshold of Systemic MAGE-A Gene Expression Predicting Survival in Resected Non-Small Cell Lung Cancer. | Mecklenburg, I., et al. 2017. Clin Cancer Res. 23: 1213-1219. PMID: 27542766
- MAGE-A Antigens and Cancer Immunotherapy. | Zajac, P., et al. 2017. Front Med (Lausanne). 4: 18. PMID: 28337438
- Expression of cancer/testis antigens MAGE-A, MAGE-C1, GAGE and CTAG1B in benign and malignant thyroid diseases. | Melo, DH., et al. 2017. Oncol Lett. 14: 6485-6496. PMID: 29163685
- MAGE-A gene expression in peripheral blood serves as a poor prognostic marker for patients with lung cancer. | Gu, L., et al. 2018. Thorac Cancer. 9: 431-438. PMID: 29430849
- MAGE-A expression in oral and laryngeal leukoplakia predicts malignant transformation. | Baran, CA., et al. 2019. Mod Pathol. 32: 1068-1081. PMID: 30936424
- Analysis of the function of MAGE-A in esophageal carcinoma by bioinformatics. | Chen, X., et al. 2019. Medicine (Baltimore). 98: e15774. PMID: 31124967
- MAGE-A genes as predictors of the outcome of laryngeal squamous cell carcinoma. | Liu, S., et al. 2020. Oncol Lett. 20: 59. PMID: 32793312
- Melanoma Antigen Family A (MAGE A) as Promising Biomarkers and Therapeutic Targets in Bladder Cancer. | Verma, S., et al. 2024. Cancers (Basel). 16: PMID: 38254738
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
MAGE-A Antibody (A-1) | sc-515687 | 200 µg/ml | $316.00 | |||
MAGE-A Antibody (A-1): m-IgG Fc BP-HRP Bundle | sc-531469 | 200 µg Ab; 10 µg BP | $354.00 | |||
MAGE-A Antibody (A-1): m-IgGκ BP-HRP Bundle | sc-525164 | 200 µg Ab, 40 µg BP | $354.00 | |||
MAGE-A Antibody (A-1) AC | sc-515687 AC | 500 µg/ml, 25% agarose | $416.00 | |||
MAGE-A Antibody (A-1) HRP | sc-515687 HRP | 200 µg/ml | $316.00 | |||
MAGE-A Antibody (A-1) FITC | sc-515687 FITC | 200 µg/ml | $330.00 | |||
MAGE-A Antibody (A-1) PE | sc-515687 PE | 200 µg/ml | $343.00 | |||
MAGE-A Antibody (A-1) Alexa Fluor® 488 | sc-515687 AF488 | 200 µg/ml | $357.00 | |||
MAGE-A Antibody (A-1) Alexa Fluor® 546 | sc-515687 AF546 | 200 µg/ml | $357.00 | |||
MAGE-A Antibody (A-1) Alexa Fluor® 594 | sc-515687 AF594 | 200 µg/ml | $357.00 | |||
MAGE-A Antibody (A-1) Alexa Fluor® 647 | sc-515687 AF647 | 200 µg/ml | $357.00 | |||
MAGE-A Antibody (A-1) Alexa Fluor® 680 | sc-515687 AF680 | 200 µg/ml | $357.00 | |||
MAGE-A Antibody (A-1) Alexa Fluor® 790 | sc-515687 AF790 | 200 µg/ml | $357.00 |